Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Cutan Aesthet Surg ; 13(3): 257-258, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33209009

RESUMEN

Full-thickness skin grafts harvested from hair-bearing areas may negatively impact cosmetic outcomes if the recipient site is hairless. Intraoperative depilation of unwanted hair follicles using an electrosurgical device can permanently remove hair with a single treatment and improve overall cosmesis.

2.
Cutis ; 99(3): E36-E39, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28398427

RESUMEN

Disseminated superficial actinic porokeratosis (DSAP) is a chronic condition characterized by numerous atrophic papules and patches with a distinctive peripheral keratotic ridge, typically found on sun-exposed areas. Treatment of DSAP is warranted not only for cosmetic and symptomatic benefits but also to prevent malignant transformation. Successful treatment of DSAP often is difficult and frequently requires the use of multiple modalities. Ingenol mebutate gel 0.05% is a topical medication primarily used for the treatment of actinic keratosis (AK) by inducing cell death. We report a case of DSAP treated effectively with ingenol mebutate gel 0.05%.


Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Diterpenos/uso terapéutico , Poroqueratosis/tratamiento farmacológico , Administración Cutánea , Adulto , Fármacos Dermatológicos/administración & dosificación , Diterpenos/administración & dosificación , Femenino , Geles , Humanos , Poroqueratosis/patología , Resultado del Tratamiento
3.
J Drugs Dermatol ; 13(4): 391-5; quiz 396, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24719057

RESUMEN

Approximately 20-25% of the population worldwide is affected by superficial cutaneous mycoses (SCM). SCM are cutaneous fungal infections with a wide array of systemic and topical treatment options. However, successful therapeutic outcomes are limited by patient non-adherence, medication side effects, potential drug interactions, antifungal resistance and disease recurrence. Advances in formulation technology have allowed for the development of more effective and safer therapies. In this article we will review several new and emerging pharmacotherapeutics for onychomycosis and tinea pedis.


Asunto(s)
Antifúngicos/uso terapéutico , Onicomicosis/tratamiento farmacológico , Tiña del Pie/tratamiento farmacológico , Alilamina/análogos & derivados , Alilamina/uso terapéutico , Compuestos de Boro/uso terapéutico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Educación Médica Continua , Humanos , Imidazoles/uso terapéutico , Itraconazol/uso terapéutico , Triazoles/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA